Olumiant meets Phase III endpoints for atopic dermatitis

Eli Lilly and Co. (NYSE:LLY) and Incyte Corp. (NASDAQ:INCY) said Olumiant baricitinib met the primary endpoints

Read the full 164 word article

User Sign In